AMIX

Autonomix Medical

AMIX

Market cap $6.55M

Overview Fund Activity

1.16 USD

+0.02

1.75%

At close Updated Sep 17, 4:00 PM EDT

Pre-market

After hours

1.15

-0.01

0.86%

1 day

1.75%

5 days

0.87%

1 month

3.57%

3 months

-4.92%

6 months

-41.71%

Year to date

-65.58%

1 year

-91.93%

5 years

-98.86%

10 years

-98.86%

About: Autonomix Medical Inc is a development-stage medical device development company focused on advancing technologies for sensing and treating disorders relating to the nervous system. Its first-in-class technology platform includes a catheter-based microchip-enabled array that can detect and differentiate neural signals with a high degree of sensitivity as demonstrated in animal studies.

Employees: 11

Healthcare Medical Devices

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

200% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 3

50% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 2

46% more funds holding

Funds holding: 13 [Q1] → 19 (+6) [Q2]

20% more capital invested

Capital invested by funds: $144K [Q1] → $173K (+$29K) [Q2]

0.16% more ownership

Funds ownership: 6.26% [Q1] → 6.43% (+0.16%) [Q2]

See Fund Rankings

Financial journalist opinion

Based on 3 articles about AMIX published over the past 30 days

Autonomix Medical, Inc. (NASDAQ: AMIX) Participates in Virtual Investor “What This Means” Segment

Dr. Robert Schwartz, Chief Medical Officer of Autonomix, discusses the Company's recently announced results from the post hoc analysis of its proof-of-concept human clinical trial (“PoC 1”)

Autonomix Medical, Inc. (NASDAQ: AMIX) Participates in Virtual Investor “What This Means” Segment

Autonomix Medical, Inc. Demonstrates Sustained Pain Reduction, Quality of Life Gains and 100% Zero Opioid Use in Longer-Term Post Hoc Analysis from PoC 1 Study

New longer-term post hoc analysis results of responders (n=6) 1 showed long-lasting, durable pain reduction of nearly 66%, or a mean 5.08 reduction on the VAS pain scale, in patients with severe pancreatic cancer pain

Autonomix Medical, Inc. Demonstrates Sustained Pain Reduction, Quality of Life Gains and 100% Zero Opioid Use in Longer-Term Post Hoc Analysis from PoC 1 Study

Autonomix Medical, Inc. to Present at H.C. Wainwright 27th Annual Global Investment Conference

THE WOODLANDS, TX, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that Brad Hauser, Chief Executive Officer of Autonomix will present at the H.C. Wainwright 27 th Annual Global Investment Conference being held September 8-10, 2025 in New York, NY.

Autonomix Medical, Inc. to Present at H.C. Wainwright 27th Annual Global Investment Conference

Autonomix Medical, Inc. to Participate in Virtual Investor Webinar Hosted by Ladenburg Thalmann & Co. Inc.

Live video webcast on Thursday, August 21 st at 1:00 PM ET Register here THE WOODLANDS, TX, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted treatments, today announced that Brad Hauser, President and Chief Executive Officer will participate in a virtual investor webinar hosted by Ladenburg Thalmann on Thursday, August 21, 2025 and 1:00 PM ET. The webinar will be moderated by Jeffrey S.

Autonomix Medical, Inc. to Participate in Virtual Investor Webinar Hosted by Ladenburg Thalmann & Co. Inc.

Autonomix Medical, Inc. to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

– Live video webcast on Thursday, August 21 st at 2:20 PM ET THE WOODLANDS, TX, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted treatments, today announced that it will present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech being held virtually August 19-21, 2025. Details for the presentation are as follows: Date and Time: Thursday, August 21, 2025 at 2:20 PM ET Presenter: Brad Hauser, President and Chief Executive Officer Registration Link: HERE About Webull Financial Webull Financial is a leading online brokerage platform committed to empowering self-directed investors with innovative tools and cutting-edge technology.

Autonomix Medical, Inc. to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Autonomix Medical, Inc. Finalizes Design Review of First-Ever Intravascular Nerve Sensing Catheter in Key Step Toward U.S. Clinical Studies

Microchip-based platform enables real-time nerve mapping and targeted treatment from within the vascular system Continued progress toward submitting Investigational Device Exemption (“IDE”), and if approved, the commencement of U.S. clinical trials to support a De Novo FDA application THE WOODLANDS, TX, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced it has advanced its proprietary sensing catheter through a final design review in preparation for human clinical trials. Previous versions had been used in animal models to demonstrate the ability to detect nerve signals.

Autonomix Medical, Inc. Finalizes Design Review of First-Ever Intravascular Nerve Sensing Catheter in Key Step Toward U.S. Clinical Studies

Zacks Investment Research

Autonomix Medical, Inc. (AMIX) Upgraded to Strong Buy: Here's Why

Autonomix Medical, Inc. (AMIX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Autonomix Medical, Inc. (AMIX) Upgraded to Strong Buy: Here's Why

Autonomix Medical, Inc. Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

– Video webcast now available on-demand THE WOODLANDS, TX, July 22, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that Brad Hauser, Chief Executive Officer of Autonomix, participated in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference. For the event, Mr.

Autonomix Medical, Inc. Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Autonomix Medical, Inc. Granted New U.S. Patent to Advance Minimally Invasive, Nerve-Focused Treatments Across High-Need Indications

With over 80 issued patents and 40 pending patent applications, Autonomix is building a comprehensive IP portfolio in nerve-sensing and modulation, strengthening its strategic position in a multi-billion-dollar market opportunity and unlocking potential across cardiovascular, renal, and other high-burden diseases

Autonomix Medical, Inc. Granted New U.S. Patent to Advance Minimally Invasive, Nerve-Focused Treatments Across High-Need Indications

Autonomix Medical, Inc. Announces Release of the Next CEO Corner Segment

THE WOODLANDS, TX, July 07, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the next CEO Corner segment has been published on the Company's website. For the CEO Corner segment, Brad Hauser, CEO of Autonomix, elaborates on the Company's recently announced planned follow-on market expansion study phase (“PoC 2”) of its proof-of-concept trial.

Autonomix Medical, Inc. Announces Release of the Next CEO Corner Segment

See News Rankings

Charts implemented using Lightweight Charts™